Nebenwirkungen · Comirnaty
Comirnaty XFG 30 micrograms/dose dispersion for injection Comirnaty XFG 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty XFG 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 155
HOS-149174 · Präparat HOS-099980
Concomitant administration with seasonal influenza vaccine In Study 8, a Phase 3 study, participants 18 through 64 years of age who received Comirnaty coadministered with seasonal inactivated influenza vaccine (SIIV), quadrivalent followed 1 month later by placebo, were compared to participants who received an inactivated influenza vaccine with placebo followed 1 month later by Comirnaty alone (n = 553 to 564 participants in each group).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage fec9094bd716ae93e1a34850d0204e6c87340eebb4eec28d7b1a0b209b3fe79b · Zeichen 20505–20946 im Abschnitt